The invention relates to self-assembled organosilane- and small molecule drug-containing coatings for resorbable medical implant devices. The coatings can be prepared from precursor compositions containing an organosilane and a small molecule drug, and can be applied to substrates. Prior to applying the coatings, the surfaces of the substrates can be pretreated. The coatings can be functionalized with a binding compound that is coupled with an active component. The coatings can be applied using various techniques and apparatus, more particularly, by a deep-coating process conducted at ambient conditions.

Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers.

Disclosed are methods of promoting wound healing in a patient in need thereof comprising administering to the patient a composition comprising a neonatal fibrin scaffold. Further disclosed are in vitro methods for evaluating a target composition on human wound healing comprising a neonatal porcine plasma scaffold with the target composition and evaluating scaffold properties of the plasma sample.

Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.

The disclosure relates to an in situ-gelling hydrogel composition based on functionalized zwitterionic polymers. The resulting hydrogels exhibit highly anti-fouling, anti-adhesive, and lubricating properties to enable the fabrication of bulk hydrogels or hydrogel-based coatings of relevance to biomedical applications.

In a method of integrating an active pharmaceutical ingredient (API) with a thermoplastic polymer, the thermoplastic polymer and API are into a first feed port of a multi-screw extruder or the thermoplastic polymer is fed into the first feed port of a multi-screw extruder, the thermoplastic polymer is conveyed along the heated multi-screw extruder while heating the thermoplastic polymer to a melt temperature of 160° C.-280° C. prior to the thermoplastic polymer being conveyed past a second feed port and the API is fed into the second feeding port in the heated screw extruder to mix with the melted thermoplastic polymer to generate a compounded mixture containing 85-100% of the starting API content. The compounded mixture is extruded from an outlet of the heated screw extruder and cooled via a cooling device such that the compounded mixture contains 85-100% of the starting API content.

Disclosed herein are delivery systems including coated and uncoated yarns, yarn precursors, threads, fibers, and other substrates for the constant or near-constant release of active compounds, as well as methods for manufacturing such delivery systems. The yarns, yarn precursors, threads, fibers, and other substrates can include a cross-linked hydrophobic elastomer and an active compound. One or more coatings that are impermeable or substantially impermeable to the active compound may partially or fully occlude the yarn or substrate to control release rates of the active compound. The delivery systems may be used in a variety of applications, including the making of articles of clothing, textiles, and fabrics, and may be used in methods of treating various conditions and diseases.

A biocompatible adhesive is disclosed. The biocompatible adhesive includes a substrate and a plurality of micro-scale elements extending from a surface of the substrate having a length selected to puncture a layer of a target tissue or target material. At least some of the micro-scale elements include at least one protrusion dimensioned to anchor the biocompatible adhesive to the target tissue or target material. A medical device assembly is also disclosed. The medical device assembly includes the biocompatible adhesive coupled to a surface of a component of the medical device assembly and positioned to attach the medical device assembly to the target tissue or target material. A method of facilitating attachment of a medical device assembly to a target tissue is also disclosed. A method of facilitating treatment of a wound is also disclosed.

It has been established that optimizing cell seeding onto tissue engineering vascular grafts (TEVG) is associated with reduced inflammatory responses and reduced post-operative stenosis of TEVG. Cell seeding increased TEVG patency in a dose dependent manner, and TEVG patency improved when more cells were seeded, however duration of incubation time showed minimal effect on TEVG patency. Methods of engineering patient specific TEVG including optimal numbers of cells to maintain graft patency and reduce post-operative stenosis are provided. Closed, single-use customizable systems for seeding TEVG are also provided. Preferably the systems are custom-designed based on morphology of the patient specific graft, to enhance the efficacy of cell seeding.

Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues) and an additive.